Analysis of Fecal Metagenomics and Plasma Metabolomics Uncovers Alterations in Gut Microbiota and Plasma Metabolite Profiles in Rats Experiencing Diarrhea Induced by Abemaciclib - Takeaways - MDSpire

Analysis of Fecal Metagenomics and Plasma Metabolomics Uncovers Alterations in Gut Microbiota and Plasma Metabolite Profiles in Rats Experiencing Diarrhea Induced by Abemaciclib

  • By

  • Ling Ye

  • Li Cao

  • Qiong Du

  • Rui Xu

  • Yu Han

  • Jiyong Liu

  • January 19, 2026

  • 0 min

Share

  • 1

    Abemaciclib, a CDK 4/6 inhibitor, is effective for treating HR+/HER2− breast cancer but causes significant gastrointestinal toxicity, particularly diarrhea.

  • 2

    Diarrhea induced by abemaciclib affects 80%-90% of patients, leading to malnutrition, fatigue, and potential treatment discontinuation.

  • 3

    The study investigates gut microbiota and plasma metabolite changes in rats to understand the mechanisms behind abemaciclib-induced diarrhea.

  • 4

    Rats administered 150 mg/kg/day of abemaciclib developed severe diarrhea, allowing for a controlled study of its effects on gut health.

  • 5

    Findings from this research aim to enhance clinical management of abemaciclib and inform strategies to address gut microbiota imbalances.

Original Source(s)

Analysis of Fecal Metagenomics and Plasma Metabolomics Uncovers Alterations in Gut Microbiota and Plasma Metabolite Profiles in Rats Experiencing Diarrhea Induced by Abemaciclib

  • by Ling Ye, Li Cao, Qiong Du, Rui Xu, Yu Han, Jiyong Liu

  • January 19, 2026

Related Content

Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study

A structural mean modeling Mendelian randomization approach to investigate the lifecourse effect of adiposity: applied and methodological considerations

Roswell Park is Hiring!

Working at Roswell Park will afford you incredible opportunities to work alongside some of the nation’s foremost clinicians and researchers to broaden your career experiences and be part of a team that eases the burden of cancer.

  • by

  • May 19, 2025

  • 1 min